益方生物：预计2025年度净亏3.17亿元

Core Viewpoint - The company anticipates a revenue of 37.3253 million yuan for the fiscal year 2025, while projecting a net loss of 316.8384 million yuan attributable to the parent company [1] Group 1: Financial Projections - Expected revenue for 2025 is 37.3253 million yuan [1] - Projected net loss for 2025 is 316.8384 million yuan [1] Group 2: Research and Development - The company maintains a high level of R&D investment during the reporting period [1] - Revenue from technology licensing and cooperation is currently insufficient to cover costs and expenses [1] Group 3: Business Stability - Despite the anticipated losses, the company's core business and competitive advantages have not experienced significant adverse changes [1]